Citations

Clear

8 citation(s) found for "Coleman, Eli".

Update on curriculum standards for sexual health education, impact, and platforms for medical training: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024)
Parish, Sharon J. , Kling, Juliana M. , Coleman, Eli , Eardley, Ian , Bober, Sharon L. , Heruti, Rafi, Rubio‐Aurioles, Eusebio, Reisman, Yacov , Kling, Juliana M , Heruti, Rafi, Rubio‐Aurioles, Eusebio

Mayo Clinic

Sexual Medicine Reviews | May 16, 2026 | Volume: 14 | Issue: 3 | Pages: No page available

10.1093/sxmrev/qeag030 | PMID 42485646 Get It

Abstract Introduction Sexual problems are common throughout the lifespan. Therefore, it is important for medical students and other health professionals to receive instruction in sexual medicine that is sufficient to prepare them to address these issues as a routine part of practice. Objectives To consolidate and update recommendations published from prior International Consultations on Sexual Medicine and other consensus-based recommendations from across the world for standards of sexual health education (SHE) among medical students. To evaluate the status of recommendations for various health professionals and of existing training and educational platforms. Methods A conceptual review of previous reports on curriculum standards of SHE in medical schools and an updated literature review from 2016 to current was conducted. Results We provide a summary and comprehensive recommendations based on expert opinion, accumulated experience, and literature review for a sexual health curriculum for medical students, including how it should be taught, recognizing that curricula are diverse worldwide. Scant research exists regarding the impact of sexual medicine training on sustained clinical skills and patient outcomes. Existing sexual medicine education platforms can be applied, adapted, and optimized across training levels, disciplines, and geographic locations. We discuss opportunities to improve evaluation of knowledge and competency, as well as the importance of studying methodologies to improve curriculum and methods of evaluation, particularly for disciplines in which these curricula have not previously been evaluated. Conclusions Sexual medicine societies are encouraged to implement previous recommendations and make medical student SHE a priority. Extending these recommendations to post-graduate and practicing clinician and other health professionals’ education would help close education and clinical practice gaps. Future training interventions should incorporate assessment of skill acquisition and meaningful patient outcomes, as well as integrate educational platforms including web-based formats, interactive technology, and experiential learning strategies. Recommendations of Expert Consensus Committee Sexual health educational curricula should be expanded to include sexual well-being and pleasure in addition to pregnancy and sexually transmitted infection (STI) prevention. (Strong) ISSM and affiliated sexual medicine societies (ASMS) should follow through on previous recommendations (ICSM 2009, 2016) and prioritize sexual health education in their missions. (Strong) Sexual medicine societies should join with other organizations to promote standards through position statements and other joint efforts. (Strong) ISSM/ASMS should play a key role in setting curriculum standards, promoting sexual health education in medical schools and other health professions, providing teaching methods and materials, and training of educators. (Strong) ISSM/ASMS are encouraged to establish standing committees promoting sexual medicine education in medical schools, other health professions, and graduate/postgraduate training. (Weak) ISSM/ASMS should utilize international, regional, and virtual meetings as vehicles for disseminating updated knowledge and training educators. (Strong) ISSM/ASMS should advocate to regulatory organizations that set standards for the requirement of sexual health training and assessment of competency in all professions. (Strong) The committee encourages exploration of the use of digital interactive platforms and modern technologies (avatars, AI -artificial intelligence, NLP -natural language processing) and inclusion of quality assurance of virtual domains. (Weak) Beyond the evaluation of student and postgraduate trainee performance and curricula effectiveness, the committee urges research on the impact of educational interventions on sustained clinical practices and patient outcomes in sexual health. (Strong)
Therapeutic Treatment Planning for Sex Therapy Using the Sexual Health and Integrative Pleasure (SHIP) Model
Connor, Jennifer J. , Arenella, Katherine , Oliveira, Leonor de , Evenson, LynAnne, Mark, Kristen P. , Newstrom, Nicholas P. , Robinson, Beatrice “Bean” E., Vencill, Jennifer A. , Girard, Abby , Connor, Jennifer Jo

Mayo Clinic

Journal of Sex & Marital Therapy | July 8, 2025 | Volume: 51 | Issue: 6 | Pages: 629-638

10.1080/0092623x.2025.2531161 | PMID 40625285 Get It

The goals and needs of qualitative research in sexual medicine: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024)
Bober, Sharon L. , Reisman, Yacov , Heruti, Rafi, Rubio‐Aurioles, Eusebio , Coleman, Eli , Eardley, Ian , Parish, Sharon J. , Kling, Juliana M.

Mayo Clinic

Sexual Medicine Reviews | July 3, 2025 | Volume: 13 | Issue: 4 | Pages: 538-547

10.1093/sxmrev/qeaf041 | PMID 40795836 Get It

Abstract Introduction As the field of sexual medicine continues to grow, there has been increasing attention on methodological integrity and rigor of sexual medicine research, including an emphasis on guidelines for quantitative research design and standards for assessing clinical trial outcomes. However, qualitative research (QR) methodology has garnered relatively scant attention in comparison. Objectives To clarify the value of QR and provide recommendations for improving implementation of QR methods in sexual medicine research. Methods A PubMed review was conducted. Expert opinion was based on a process of literature review and expert consensus. Results An essential goal of QR is to describe and explain unknown or insufficiently understood phenomena through detailed investigation of subjective human experience. Results from QR allow for generating hypotheses that may then be tested. More recently, mixed-methods research, ie, research integrating both qualitative and quantitative methods, is being increasingly used across domains of biomedical and health science research. While there remain differences of opinion regarding use of qualitative methodology in sexual medicine, best-practice models of QR underscore the principle of trustworthiness and include ethics and transparency in protocols for data collection and analysis. It is recommended that established QR frameworks for developing a research question are utilized and that consolidated criteria for reporting research results are employed. Furthermore, authors and reviewers need training in both QR methods and qualitative reporting frameworks to be able to adequately report and review this type of research. Specific areas in sexual medicine that would ideally benefit from QR methods are suggested. Conclusion As the field of sexual medicine continues to expand, qualitative methodologies including mixed-methods research, offer significant value for understanding domains of inquiry that have not been thoroughly investigated. To achieve these targets, training of authors and reviewers on QR is needed.
Sexual Health and Integrative Pleasure (SHIP) Model: Using a clinical case example to guide assessment and treatment
Girard, Abby , Newstrom, Nicholas P. , Connor, Jennifer J. , Arenella, Katherine , Vencill, Jennifer A. , Robinson, Beatrice “Bean” E., Vencill, Jennifer, Connor, Jennifer Jo

Mayo Clinic

Journal of Marital and Family Therapy | December 9, 2022 | Volume: 49 | Issue: 2 | Pages: 333-350

10.1111/jmft.12624 | PMID 36490320 Get It

AbstractThis manuscript presents a conceptual model—the Sexual Health and Integrative Pleasure (SHIP) Model—for the clinical assessment and intervention of sexual health concerns. The model was developed by a group of couple/marital family therapy and psychologists who specialize in the treatment of sexual problems. The model consists of five philosophical foundations (systems framework, intersectionality, biopsychosocial model, lifespan approach, and empiricism) and five core therapeutic components (sexual literacy, sexual adaptation and resilience, relational intimacy, pleasure‐oriented positive sexuality, and multidisciplinary care). We define each foundation and component, and compare and contrast the SHIP model with other existing sexual health models. Finally, we demonstrate how the SHIP model was used to provide individual and couple therapy with a cis/heterosexual couple in a university‐based sexual health clinic and make recommendations for additional clinical applications of the model.
Standards of Care for the Health of Transgender and Gender Diverse People, Version 8
Coleman, Eli , Bouman, Walter Pierre , Brown, George R. , Vries, A. de , Deutsch, Madeline B. , Ettner, Randi, Fraser, Lin, Goodman, Michael , Green, J., Hancock, Adrienne B. , Johnson, Thomas W. , Karasic, Dan H., Knudson, Gail, Leibowitz, Scott , Meyer‐Bahlburg, Heino F. L. , Monstrey, S., Motmans, Joz , Nahata, Leena , Reisner, Sari L. , Richards, Christina , Schechter, Loren S. , Tangpricha, Vin , Tishelman, Amy C. , Trotsenburg, M.A.A. van , Winter, Sam , Ducheny, Kelly , Adams, Noah S. , Adrián, T. M., Allen, Luke R. , Azul, David , Bagga, Harjit, Başar, Koray , Bathory, D. S., Belinky, Javier, Berg, Dianne , Berli, Jens U. , Bluebond‐Langner, Rachel , Bouman, Mark‐Bram , Bowers, Marci, Brassard, P., Byrne, Jack, Cargill, C. J., Carswell, Jeremi M. , Chang, Sand C. , Chelvakumar, Gayathri, Corneil, Trevor , Dalke, Katharine B. , Cuypere, Griet De , Vries, Elma De , Devor, Aaron , D’Marco, A., Edmiston, E. Kale , Edwards-Leeper, Laura, Ehrbar, Randall D., Ehrensaft, Diane , Eisfeld, Justus, Elaut, Els , Erickson‐Schroth, Laura, Feldman, Jamie , Garcia, Maurice M. , Gijs, Luk , Green, S. E., Hall, B. P., Hardy, Teresa L. D. , Jacobs, Laura A., Klink, Daniel, Kuper, Laura E. , Kvach, Elizabeth, Malouf, Matthew A., Massey, Ren, Mazur, Tom, McLachlan, Chris tine, Mosser, Scott W., Neira, Paula M. , Nygren, Ulrika , Oates, Jennifer , Pagkalos, Georgios, Patton, J., Rachlin, Katherine, Reed, T., Rider, G. Nic , Ristori, Jiska , Robbins-Cherry, Sally, Roberts, Stephanie , Sabir, K., Seal, Leighton , Sehoole, T. J. , Spencer, K., Amand, Colt St. , Strang, John F. , Taylor, G. B., Vala, L. N., Vencill, Jennifer A. , Wesp, Linda , Rider, G. Nic , Tangpricha, Vin , Roberts, Stephanie A , Radix, Asa E. , Nieder, Timo Ole , Capitán, Luis Pérez , Heijer, Martin den , Dhejne, Cecilia , Fisher, Alessandra D. , Irwig, Michael S. , Jacobs, L. A., Janssen, Aron C. , Johnson, Katherine , Kreukels, Baudewijntje P.C. , McLachlan, Christine , Morrison, Shane D. , Obedin‐Maliver, Juno , Phanuphak, Nittaya , Reed, T., Rodriguez-Wallberg, Kenny A , Rosenthal, Stephen M. , Safer, Joshua D. , Scheim, Ayden I. , Steensma, Thomas D. , Tilleman, Kelly , T’Sjoen, Guy , Mello, Norah M. van , Veale, Jaimie F. , Vincent, Ben , West, Michael A. , Arcelus, Jon

Mayo Clinic

International Journal of Transgender Health | September 6, 2022 | Volume: 23 | Issue: sup1 | Pages: S1-S259

10.1080/26895269.2022.2100644 | PMID 36238954 Get It

Randomized, open-label, phase III study of pemetrexed plus carboplatin followed by maintenance pemetrexed (Arm A) versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab (Arm B) in patients with advanced nonsquamous (NS) non-
Zinner, Ralph , Ross, Helen J. , Weaver, Robert, Holden, Viran, Chowhan, N. M., Modiano, Manuel, Rao, Vijay Phooshkooru, Koustenis, Andrew, Melemed, Symantha, Guba, Susan C., Ortuzar, Waldo Feliu, Desaiah, D., Obasaju, Coleman K., Govindan, Ramaswamy , Beck, J. Thaddeus , Waterhouse, David , Liu, Jingyi , Spigel, David R.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: LBA8003-LBA8003

10.1200/jco.2013.31.15_suppl.lba8003 Get It

LBA8003 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.
Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell l
Zinner, Ralph , Ross, Helen J. , Weaver, Robert, Holden, Viran, Chowhan, N. M., Modiano, Manuel, Rao, Vijay Phooshkooru, Koustenis, Andrew, Melemed, Symantha, Guba, Susan C., Ortuzar, Waldo Feliu, Desaiah, D., Obasaju, Coleman K., Govindan, Ramaswamy , Beck, J. Thaddeus , Waterhouse, David , Liu, Jingyi , Spigel, David R.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 31 | Issue: 18_suppl | Pages: LBA8003-LBA8003

10.1200/jco.2013.31.18_suppl.lba8003 Get It

LBA8003 Background: PemC and PCB are regimens used for first-line treatment of advanced NS-NSCLC. The primary objective was to compare progression-free survival without Grade 4 toxicity (G4PFS) between two vs three drug regimen arms. Methods: Patients ≥18 years, Stage IV NS NSCLC, AJCC (v7.0), and ECOG PS 0/1 were enrolled. Patients were randomized (1:1); received 4 cycles of induction (PemC: Pem, 500 mg/m2 and C, AUC = 6; PCB: P, 200 mg/m2, C, AUC = 6, and B, 15 mg/kg) followed by Pem (PemC Arm) or B (PCB Arm) maintenance therapy in the absence of progressive disease or discontinuation. Secondary endpoints were PFS, overall survival (OS), overall response rate (ORR), and disease control rate (DCR). The study was powered for G4PFS; assuming hazard ratio (HR) of 0.75; there was 80% power to detect superiority of PemC over PCB with a 2-sided type I error of 0.10. Efficacy data were analyzed by intent-to-treat principle using the log-rank test for time-to-event variables, and an exact test for ORR and DCR. Safety data were evaluated using CTCAE v3 for patients who received ≥1 dose of study treatment. Results: Patients were randomized to PemC (N = 182) or PCB (N = 179). Baseline factors were balanced between arms: median age 66/66 years; % female 42/42; % PS=0, 47/47; % stage IV M1a 29/30; for PemC vs PCB, median G4PFS (months) was 3.91/2.86 (HR = 0.85, 90% CI 0.7, 1.04, p = 0.176); PFS and OS had HR = 1.06 (95% CI 0.84, 1.35), p = 0.610, and HR = 1.07 (95% CI 0.83, 1.36), p = 0.616, respectively. The ORR (%) 23.6/ 27.4 and DCR (%) 59.9/57.0 were for PemC vs PCB, respectively. Significantly more drug-related grade 3/4 anemia (18.7% vs 5.4%), and thrombocytopenia (24.0% vs 9.6%) were seen on PemC; significantly more grade 3/4 neutropenia (48.8% vs 24.6%) and grade 1/2 alopecia (28.3 % vs 8.2%) were seen on PCB. Conclusions: PemC was not superior to PCB in G4PFS; no difference in PFS or OS was observed for the two- vs three-drug regimens. There were no unexpected toxicities; the toxicity profiles demonstrated distinctions by arm, and both regimens demonstrated tolerability. Clinical trial information: NCT00948675.
Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non–Small-Cell Lung Cancer
Cynthia, X. , Thomas, Sachdev , Mandrekar, Sumithra J. , Nikcevich, Daniel A., Rowland, Kendrith M. , Fitch, Tom R., Windschitl, Harold E., Hillman, Shauna L., Schild, Steven E. , Jett, James R., Obasaju, Coleman K., Adjei, Alex A. , Nair, Suresh , Schild, Steven

Mayo Clinic

Journal of Clinical Oncology | August 31, 2005 | Volume: 23 | Issue: 25 | Pages: 5929-5937

10.1200/jco.2005.13.953 | PMID 16135464 Get It

Purpose A randomized three-arm phase II study was undertaken to evaluate the optimum administration schedule of pemetrexed and gemcitabine in chemotherapy-naïve patients with non–small-cell lung cancer. Patients and Methods Patients were randomly assigned to three schedules of pemetrexed 500 mg/m2 plus gemcitabine 1,250 mg/m2, separated by a 90-minute interval, on a 21-day cycle as follows: schedule A, pemetrexed followed by gemcitabine on day 1 and gemcitabine on day 8; schedule B, gemcitabine followed by pemetrexed on day 1 and gemcitabine on day 8; and schedule C, gemcitabine on day 1 and pemetrexed followed by gemcitabine on day 8. Results One hundred fifty-two eligible patients (schedule A, n = 59; schedule B, n = 31, and schedule C, n = 62) received a median of five (schedule A), two (schedule B), and four (schedule C) treatment cycles. Overall, 66% of patients experienced grade 3 or 4 neutropenia. Common grade 3 and 4 nonhematologic toxicities were dyspnea (11%), fatigue (16%), and transaminase elevation (9%). Schedule A seemed less toxic compared with schedule C (grade 3 or 4 events: 86% v 94%, respectively; P = .19; grade 4 events: 39% v 48%, respectively; P = .30). Schedule B was closed at interim analysis for inferior efficacy. Schedule A, with a confirmed response rate of 31% (95% CI, 20% to 45%), met the protocol-defined efficacy criteria, whereas schedule C, with a confirmed response rate of 16.1% (95% CI, 11% to 34%), did not. Median survival time and time to progression were 11.4 and 4.4 months, respectively, with no observable difference between the arms. Conclusion Pemetrexed and gemcitabine administered as outlined for schedule A met the protocol-defined efficacy criteria, was less toxic compared with the other treatment schedules, and should be further evaluated.